GSK in $350 million deal to develop cancer drugs with UK biotech firm: FT

(Reuters) - GlaxoSmithKline Plc has agreed a deal worth more than $350 million with UK biotech company Adaptimmune to develop cancer drugs, the Financial Times reported on Monday.

from Reuters: Deals http://ift.tt/1oLvAQk